Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy-Reference-Cited by-同舟云学术

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Published:2018-05 Issue:5 Volume:29 Page:1220-1226
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kang Y.-K.,Ryu M.-H.,Park S.H.,Kim J.G.^ORCID,Kim J.W.,Cho S.-H.,Park Y.-I.,Park S.R.,Rha S.Y.,Kang M.J.,Cho J.Y.,Kang S.Y.,Roh S.Y.,Ryoo B.-Y.,Nam B.-H.,Jo Y.-W.,Yoon K.-E.,Oh S.C.

Funder

Ministry of Trade, Industry and Energy

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdy055/23857195/mdy055.pdf

Reference25 articles.

1. Paclitaxel Gastric Cancer Study Group in Japan. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer;Yamaguchi;Gastric Cancer,2002

2. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: wJOG 4007 trial;Hironaka;JCO,2013

3. Limited oral bioavailability and active epithelial secretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine;Sparreboom;Proc Natl Acad Sci USA,1997